Overview
- The University of Georgia meta-analysis, published Monday, combined 15 Phase 3 randomized trials that enrolled more than 14,000 non‑diabetic patients to compare tirzepatide, semaglutide, and liraglutide.
- Tirzepatide produced the largest mean weight loss in the pooled trials at just over 20% of starting body weight while semaglutide averaged about 15% and liraglutide about 8%.
- Authors attribute tirzepatide’s stronger effect to its dual action on GLP‑1 and GIP receptors, which affects appetite and metabolism in ways single‑receptor drugs do not.
- Reported short‑term side effects such as nausea and gastrointestinal symptoms were broadly similar across the three drugs, and tirzepatide and semaglutide use weekly dosing versus daily injections for liraglutide.
- Researchers and separate real‑world studies warn that trial results do not show long‑term durability or post‑discontinuation outcomes and that adherence, patient characteristics, and emerging multi‑receptor drugs will shape treatment choices and access.